寡核苷酸治療的全球市場 2024-2028

寡核苷酸治療市場預計在 2023-2028 年期間將成長 134.437 億美元，預測期內複合年成長率為 19.87%。

該報告包括對寡核苷酸治療市場的總體分析、市場規模和預測、趨勢、成長促進因素、挑戰以及涵蓋約 25 家供應商的供應商分析。

它提供了對當前市場狀況、最新趨勢和促進因素以及整體市場環境的最新分析。由於癌症發病率上升、對神經系統疾病個人化藥物的需求以及寡核苷酸治療藥物可用性的增加，對新型診斷方法的需求不斷增加，推動了市場的發展。

研究指出，DNA定序的進步正在增加微流體技術的採用，成為未來幾年推動寡核苷酸治療市場成長的關鍵因素之一。此外，新興經濟體的高市場成長潛力以及人工智慧在疾病評估中的日益採用導致了強勁的市場需求。

目錄

第1章執行摘要

• 市場概況

第2章 市場狀況

• 市場生態系統

第3章 市場規模評估

• 市場定義
• 細分市場分析
• 2023 年市場規模
• 2023-2028年市場展望

第4章 市場規模表現

• 2018-2022年寡核苷酸治療的全球市場
• 2018-2022年類型細分分析
• 2018-2022 年按應用分類的細分市場分析
• 2018-2022 年區域細分分析
• 2018-2022 年國家細分分析

第5章五力分析

• 五力摘要
• 買方議價能力
• 供應商的議價能力
• 新進入者的威脅
• 替代品的威脅
• 競爭威脅
• 市場狀況

第6章市場細分：依類型

• 細分市場
• 比較：按類型
• 反義寡核苷酸 (ASO)：2023-2028 年市場規模與預測
• RNAi（RNA干擾）：2023-2028年市場規模與預測
• 適體等：2023-2028年市場規模及預測
• 市場機會：按類型

第7章 市場區隔：依應用

• 細分市場
• 比較：按應用
• 神經病學：2023-2028 年市場規模與預測
• 癌症：2023-2028 年市場規模與預測
• 感染疾病等：2023-2028年市場規模及預測
• 市場機會：依應用分類

第8章 客戶狀況

• 客戶狀況概覽

第9章 地區情勢

• 區域細分
• 區域比較
• 北美：2023-2028 年市場規模與預測
• 歐洲：2023-2028 年市場規模與預測
• 亞洲：2023-2028 年市場規模與預測
• 世界其他地區：2023-2028 年市場規模與預測
• 美國：2023-2028 年市場規模與預測
• 英國：2023-2028 年市場規模與預測
• 德國：2023-2028年市場規模與預測
• 加拿大：2023-2028 年市場規模與預測
• 日本：2023-2028年市場規模與預測
• 市場機會：依地區狀況

第 10 章 促進因素、挑戰與趨勢

• 市場促進因素
• 市場挑戰
• 促進因素和挑戰的影響
• 市場趨勢

第11章 供應商情況

• 概述
• 供應商情況
• 混亂的情況
• 產業風險

第12章供應商分析

• 交易廠商
• 供應商市場定位
• Agilent Technologies Inc.
• Alnylam Pharmaceuticals Inc.
• Biogen Inc.
• CSL Ltd.
• GlaxoSmithKline Plc
• Ionis Pharmaceuticals Inc.
• Maravai LifeSciences Holdings Inc.
• Merck KGaA
• Nippon Shinyaku Co. Ltd.
• Novartis AG
• Pfizer Inc.
• Sarepta Therapeutics Inc.
• Thermo Fisher Scientific Inc.

第13章附錄

The oligonucleotide therapeutics market is forecasted to grow by USD 13443.7 mn during 2023-2028, accelerating at a CAGR of 19.87% during the forecast period. The report on the oligonucleotide therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of cancer boosts demand for novel diagnostics, need for personalized medicines for neurological disorders, and increasing availability of oligonucleotide therapeutic drugs.

Technavio's oligonucleotide therapeutics market is segmented as below:

By Type

• Antisense oligonucleotides
• RNA interference
• Aptamers and others

By Application

• Neurological
• Cancer
• Infectious diseases and others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the advances in DNA sequencing increasing adoption of microfluidic techniques as one of the prime reasons driving the oligonucleotide therapeutics market growth during the next few years. Also, high market growth potential in developing economies and growing adoption of artificial intelligence for disease evaluation will lead to sizable demand in the market.

The report on the oligonucleotide therapeutics market covers the following areas:

• Oligonucleotide therapeutics market sizing
• Oligonucleotide therapeutics market forecast
• Oligonucleotide therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oligonucleotide therapeutics market vendors that include Agilent Technologies Inc., Alnylam Pharmaceuticals Inc., Biogen Inc., CSL Ltd., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Maravai LifeSciences Holdings Inc., Merck KGaA, Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc.. Also, the oligonucleotide therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview

2 Market Landscape

• 2.1 Market ecosystem

3 Market Sizing

• 3.1 Market definition
• 3.2 Market segment analysis
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028

4 Historic Market Size

• 4.1 Global oligonucleotide therapeutics market 2018 - 2022
• 4.2 Type Segment Analysis 2018 - 2022
• 4.3 Application Segment Analysis 2018 - 2022
• 4.4 Geography Segment Analysis 2018 - 2022
• 4.5 Country Segment Analysis 2018 - 2022

5 Five Forces Analysis

• 5.1 Five forces summary
• 5.2 Bargaining power of buyers
• 5.3 Bargaining power of suppliers
• 5.4 Threat of new entrants
• 5.5 Threat of substitutes
• 5.6 Threat of rivalry
• 5.7 Market condition

6 Market Segmentation by Type

• 6.1 Market segments
• 6.2 Comparison by Type
• 6.3 Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028
• 6.4 RNA interference (RNAi) - Market size and forecast 2023-2028
• 6.5 Aptamers and others - Market size and forecast 2023-2028
• 6.6 Market opportunity by Type

7 Market Segmentation by Application

• 7.1 Market segments
• 7.2 Comparison by Application
• 7.3 Neurological - Market size and forecast 2023-2028
• 7.4 Cancer - Market size and forecast 2023-2028
• 7.5 Infectious diseases and others - Market size and forecast 2023-2028
• 7.6 Market opportunity by Application

8 Customer Landscape

• 8.1 Customer landscape overview

9 Geographic Landscape

• 9.1 Geographic segmentation
• 9.2 Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• 9.4 Europe - Market size and forecast 2023-2028
• 9.5 Asia - Market size and forecast 2023-2028
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• 9.7 US - Market size and forecast 2023-2028
• 9.8 UK - Market size and forecast 2023-2028
• 9.9 Germany - Market size and forecast 2023-2028
• 9.10 Canada - Market size and forecast 2023-2028
• 9.11 Japan - Market size and forecast 2023-2028
• 9.12 Market opportunity By Geographical Landscape

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• 11.3 Landscape disruption
• 11.4 Industry risks

12 Vendor Analysis

• 12.1 Vendors covered
• 12.2 Market positioning of vendors
• 12.3 Agilent Technologies Inc.
• 12.4 Alnylam Pharmaceuticals Inc.
• 12.5 Biogen Inc.
• 12.6 CSL Ltd.
• 12.7 GlaxoSmithKline Plc
• 12.8 Ionis Pharmaceuticals Inc.
• 12.9 Maravai LifeSciences Holdings Inc.
• 12.10 Merck KGaA
• 12.11 Nippon Shinyaku Co. Ltd.
• 12.12 Novartis AG
• 12.13 Pfizer Inc.
• 12.14 Sarepta Therapeutics Inc.
• 12.15 Thermo Fisher Scientific Inc.

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• 13.3 Currency conversion rates for US$
• 13.4 Research methodology
• 13.5 List of abbreviations

Exhibits:

• Exhibits1: Executive Summary - Chart on Market Overview
• Exhibits2: Executive Summary - Data Table on Market Overview
• Exhibits3: Executive Summary - Chart on Global Market Characteristics
• Exhibits4: Executive Summary - Chart on Market By Geographical Landscape
• Exhibits5: Executive Summary - Chart on Market Segmentation by Type
• Exhibits6: Executive Summary - Chart on Market Segmentation by Application
• Exhibits7: Executive Summary - Chart on Incremental Growth
• Exhibits8: Executive Summary - Data Table on Incremental Growth
• Exhibits9: Executive Summary - Chart on Vendor Market Positioning
• Exhibits10: Parent market
• Exhibits11: Market Characteristics
• Exhibits12: Offerings of vendors included in the market definition
• Exhibits13: Market segments
• Exhibits14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibits18: Historic Market Size - Data Table on global oligonucleotide therapeutics market 2018 - 2022 ($ million)
• Exhibits19: Historic Market Size - Type Segment 2018 - 2022 ($ million)
• Exhibits20: Historic Market Size - Application Segment 2018 - 2022 ($ million)
• Exhibits21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• Exhibits22: Historic Market Size - Country Segment 2018 - 2022 ($ million)
• Exhibits23: Five forces analysis - Comparison between 2023 and 2028
• Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• Exhibits25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• Exhibits26: Threat of new entrants - Impact of key factors in 2023 and 2028
• Exhibits27: Threat of substitutes - Impact of key factors in 2023 and 2028
• Exhibits28: Threat of rivalry - Impact of key factors in 2023 and 2028
• Exhibits29: Chart on Market condition - Five forces 2023 and 2028
• Exhibits30: Chart on Type - Market share 2023-2028 (%)
• Exhibits31: Data Table on Type - Market share 2023-2028 (%)
• Exhibits32: Chart on Comparison by Type
• Exhibits33: Data Table on Comparison by Type
• Exhibits34: Chart on Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028 ($ million)
• Exhibits35: Data Table on Antisense oligonucleotides (ASOs) - Market size and forecast 2023-2028 ($ million)
• Exhibits36: Chart on Antisense oligonucleotides (ASOs) - Year-over-year growth 2023-2028 (%)
• Exhibits37: Data Table on Antisense oligonucleotides (ASOs) - Year-over-year growth 2023-2028 (%)
• Exhibits38: Chart on RNA interference (RNAi) - Market size and forecast 2023-2028 ($ million)
• Exhibits39: Data Table on RNA interference (RNAi) - Market size and forecast 2023-2028 ($ million)
• Exhibits40: Chart on RNA interference (RNAi) - Year-over-year growth 2023-2028 (%)
• Exhibits41: Data Table on RNA interference (RNAi) - Year-over-year growth 2023-2028 (%)
• Exhibits42: Chart on Aptamers and others - Market size and forecast 2023-2028 ($ million)
• Exhibits43: Data Table on Aptamers and others - Market size and forecast 2023-2028 ($ million)
• Exhibits44: Chart on Aptamers and others - Year-over-year growth 2023-2028 (%)
• Exhibits45: Data Table on Aptamers and others - Year-over-year growth 2023-2028 (%)
• Exhibits46: Market opportunity by Type ($ million)
• Exhibits47: Data Table on Market opportunity by Type ($ million)
• Exhibits48: Chart on Application - Market share 2023-2028 (%)
• Exhibits49: Data Table on Application - Market share 2023-2028 (%)
• Exhibits50: Chart on Comparison by Application
• Exhibits51: Data Table on Comparison by Application
• Exhibits52: Chart on Neurological - Market size and forecast 2023-2028 ($ million)
• Exhibits53: Data Table on Neurological - Market size and forecast 2023-2028 ($ million)
• Exhibits54: Chart on Neurological - Year-over-year growth 2023-2028 (%)
• Exhibits55: Data Table on Neurological - Year-over-year growth 2023-2028 (%)
• Exhibits56: Chart on Cancer - Market size and forecast 2023-2028 ($ million)
• Exhibits57: Data Table on Cancer - Market size and forecast 2023-2028 ($ million)
• Exhibits58: Chart on Cancer - Year-over-year growth 2023-2028 (%)
• Exhibits59: Data Table on Cancer - Year-over-year growth 2023-2028 (%)
• Exhibits60: Chart on Infectious diseases and others - Market size and forecast 2023-2028 ($ million)
• Exhibits61: Data Table on Infectious diseases and others - Market size and forecast 2023-2028 ($ million)
• Exhibits62: Chart on Infectious diseases and others - Year-over-year growth 2023-2028 (%)
• Exhibits63: Data Table on Infectious diseases and others - Year-over-year growth 2023-2028 (%)
• Exhibits64: Market opportunity by Application ($ million)
• Exhibits65: Data Table on Market opportunity by Application ($ million)
• Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• Exhibits67: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• Exhibits69: Chart on Geographic comparison
• Exhibits70: Data Table on Geographic comparison
• Exhibits71: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibits73: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibits74: Data Table on North America - Year-over-year growth 2023-2028 (%)
• Exhibits75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibits77: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• Exhibits79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibits81: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibits87: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibits88: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibits89: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibits90: Data Table on US - Year-over-year growth 2023-2028 (%)
• Exhibits91: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibits93: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibits94: Data Table on UK - Year-over-year growth 2023-2028 (%)
• Exhibits95: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits96: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibits97: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• Exhibits99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
• Exhibits101: Chart on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
• Exhibits103: Chart on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits104: Data Table on Japan - Market size and forecast 2023-2028 ($ million)
• Exhibits105: Chart on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits106: Data Table on Japan - Year-over-year growth 2023-2028 (%)
• Exhibits107: Market opportunity By Geographical Landscape ($ million)
• Exhibits108: Data Tables on Market opportunity By Geographical Landscape ($ million)
• Exhibits109: Impact of drivers and challenges in 2023 and 2028
• Exhibits110: Overview on Criticality of inputs and Factors of differentiation
• Exhibits111: Overview on factors of disruption
• Exhibits112: Impact of key risks on business
• Exhibits113: Vendors covered
• Exhibits114: Matrix on vendor position and classification
• Exhibits115: Agilent Technologies Inc. - Overview
• Exhibits116: Agilent Technologies Inc. - Business segments
• Exhibits117: Agilent Technologies Inc. - Key news
• Exhibits118: Agilent Technologies Inc. - Key offerings
• Exhibits119: Agilent Technologies Inc. - Segment focus
• Exhibits120: Alnylam Pharmaceuticals Inc. - Overview
• Exhibits121: Alnylam Pharmaceuticals Inc. - Product / Service
• Exhibits122: Alnylam Pharmaceuticals Inc. - Key offerings
• Exhibits123: Biogen Inc. - Overview
• Exhibits124: Biogen Inc. - Product / Service
• Exhibits125: Biogen Inc. - Key news
• Exhibits126: Biogen Inc. - Key offerings
• Exhibits127: CSL Ltd. - Overview
• Exhibits128: CSL Ltd. - Business segments
• Exhibits129: CSL Ltd. - Key news
• Exhibits130: CSL Ltd. - Key offerings
• Exhibits131: CSL Ltd. - Segment focus
• Exhibits132: GlaxoSmithKline Plc - Overview
• Exhibits133: GlaxoSmithKline Plc - Business segments
• Exhibits134: GlaxoSmithKline Plc - Key news
• Exhibits135: GlaxoSmithKline Plc - Key offerings
• Exhibits136: GlaxoSmithKline Plc - Segment focus
• Exhibits137: Ionis Pharmaceuticals Inc. - Overview
• Exhibits138: Ionis Pharmaceuticals Inc. - Business segments
• Exhibits139: Ionis Pharmaceuticals Inc. - Key news
• Exhibits140: Ionis Pharmaceuticals Inc. - Key offerings
• Exhibits141: Ionis Pharmaceuticals Inc. - Segment focus
• Exhibits142: Maravai LifeSciences Holdings Inc. - Overview
• Exhibits143: Maravai LifeSciences Holdings Inc. - Business segments
• Exhibits144: Maravai LifeSciences Holdings Inc. - Key offerings
• Exhibits145: Maravai LifeSciences Holdings Inc. - Segment focus
• Exhibits146: Merck KGaA - Overview
• Exhibits147: Merck KGaA - Business segments
• Exhibits148: Merck KGaA - Key news
• Exhibits149: Merck KGaA - Key offerings
• Exhibits150: Merck KGaA - Segment focus
• Exhibits151: Nippon Shinyaku Co. Ltd. - Overview
• Exhibits152: Nippon Shinyaku Co. Ltd. - Business segments
• Exhibits153: Nippon Shinyaku Co. Ltd. - Key offerings
• Exhibits154: Nippon Shinyaku Co. Ltd. - Segment focus
• Exhibits155: Novartis AG - Overview
• Exhibits156: Novartis AG - Business segments
• Exhibits157: Novartis AG - Key news
• Exhibits158: Novartis AG - Key offerings
• Exhibits159: Novartis AG - Segment focus
• Exhibits160: Pfizer Inc. - Overview
• Exhibits161: Pfizer Inc. - Product / Service
• Exhibits162: Pfizer Inc. - Key news
• Exhibits163: Pfizer Inc. - Key offerings
• Exhibits164: Sarepta Therapeutics Inc. - Overview
• Exhibits165: Sarepta Therapeutics Inc. - Product / Service
• Exhibits166: Sarepta Therapeutics Inc. - Key offerings
• Exhibits167: Thermo Fisher Scientific Inc. - Overview
• Exhibits168: Thermo Fisher Scientific Inc. - Business segments
• Exhibits169: Thermo Fisher Scientific Inc. - Key news
• Exhibits170: Thermo Fisher Scientific Inc. - Key offerings
• Exhibits171: Thermo Fisher Scientific Inc. - Segment focus
• Exhibits172: Inclusions checklist
• Exhibits173: Exclusions checklist
• Exhibits174: Currency conversion rates for US$
• Exhibits175: Research methodology
• Exhibits176: Validation techniques employed for market sizing
• Exhibits177: Information sources
• Exhibits178: List of abbreviations